国际医学：未来公司将持续推进成本管控

Core Insights - The company is enhancing operational efficiency through clinical pathway management, reducing drug consumption ratio, and optimizing cost structure while continuously improving the quality of medical services [1] Financial Performance - As of Q3 2025, the company's management expense ratio is 10.99%, a decrease of 0.54 percentage points year-on-year and a decrease of 2.13 percentage points quarter-on-quarter [1] - The financial expense ratio stands at 3.43%, reflecting a year-on-year decrease of 0.07 percentage points and a quarter-on-quarter decrease of 0.25 percentage points, indicating initial success in cost control [1] Future Outlook - The company plans to continue its cost control efforts, with expectations for further optimization of financial costs as depreciation, amortization, and interest expenses decline [1]